SOPHiA GENETICS stock
SOPHNASDAQSOPHiA GENETICS S.A., HealthcareISIN CH1125843347
47Score 47 out of 100, Weak
Price and trend
78 / 100
Price history
+62% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 55).
The price is 16% below its 52-week high. Largest decline in 5 years: 91% (August 2021 to November 2022).
Chart figures for advanced users
- SMA 50$7.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)55
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.89
- The lowest closing price of the last twelve months.
- Resistance$8.92
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SOPHiA GENETICS S.A. belongs to the Medical (Healthcare Information Services) industry (Switzerland) and, with a market value of $635.9M, is number 18 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $77.27M (up 18.6% year on year) and a loss of $79M.
- For fiscal 2026, analysts expect on average revenue of $95.57M (up 23.7%) and adjusted earnings per share of −$0.95.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 435 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $93.65M, financial debt $61.04M.
Weaknesses
- DilutionShare count up 41% since 2020.Capital allocation 18
- Loss-makingLoss of $81.13M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$48.52M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 49 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 24.1% on the twelve months before. Revenue has grown strongly since 2019, at around 20% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 62%, operating −92%, net −102%. Last 12 months: net −89%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 2 Mar 2027in 110 days
- Last reported
- 3 Nov 2026EPS reported −$0.24 (expected −$0.20)below expectations
Analyst estimates
- Earnings per share
- −$0.95−1.1%
- Revenue
- $95.57M+0.3%
- Earnings per share
- −$0.60+4.8%
- Revenue
- $118.78M+0.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +10.7%2026 revenue guidance raised to $94 million to $96 million from $92 million to $94 million; adjusted EBITDA loss guidance of $29 million to $32 million reaffirmed.
“Given the strength of our performance in the first half of 2026, SOPHiA GENETICS is raising our full year revenue guidance for 2026 from $92 million to $94 million to $94 million to $96 million, representing 22% to 24% year-over-year growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $377,388 in total. 10 insiders sold, $4.11M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Cardoza GeorgePurchase
6 Nov 2026, Chief Financial Officer
- Shares
- 20,000
- Price
- $7.06
- Value
- $141,200
- Muken RossPurchase
6 Nov 2026, Chief Executive Officer
- Shares
- 20,000
- Price
- $6.86
- Value
- $137,188
- Xu ZhenyuSale
13 Oct 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $7.18
- Value
- $28,727
Show 73 more
- Menu PhilippeSale
12 Oct 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $7.26
- Value
- $36,303
- Camblong JurgiSale
12 Oct 2026, Executive Chairman
- Shares
- 8,500
- Price
- $7.26
- Value
- $61,671
- Van Well DaanSale
5 Oct 2026, Chief Legal Officer
- Shares
- 6,168
- Price
- $8.12
- Value
- $50,100
- Valente ManuelaSale
5 Oct 2026, Chief People Officer
- Shares
- 4,240
- Price
- $8.13
- Value
- $34,487
- Verma AbhimanyuSale
5 Oct 2026, Chief Technology Officer
- Shares
- 5,284
- Price
- $8.12
- Value
- $42,929
- Puylaert KevinSale
5 Oct 2026, Chief Sales Officer
- Shares
- 216
- Price
- $8.04
- Value
- $1,737
- Cardoza GeorgeSale
5 Oct 2026, Chief Financial Officer
- Shares
- 1,592
- Price
- $8.10
- Value
- $12,897
- Menu PhilippeSale
5 Oct 2026, Chief Medical Officer
- Shares
- 7,394
- Price
- $8.13
- Value
- $60,100
- Camblong JurgiSale
5 Oct 2026, Executive Chairman
- Shares
- 40,172
- Price
- $8.13
- Value
- $326,526
- Xu ZhenyuSale
5 Oct 2026, Chief Scientific Officer
- Shares
- 7,394
- Price
- $8.12
- Value
- $60,075
- Muken RossSale
5 Oct 2026, Chief Executive Officer
- Shares
- 9,838
- Price
- $8.13
- Value
- $79,971
- Cardoza GeorgeSale
21 Sept 2026, Chief Financial Officer
- Shares
- 774
- Price
- $8.33
- Value
- $6,447
- Muken RossSale
21 Sept 2026, Chief Executive Officer
- Shares
- 422
- Price
- $8.33
- Value
- $3,515
- Menu PhilippeSale
14 Sept 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $7.88
- Value
- $39,417
- Xu ZhenyuSale
14 Sept 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $7.88
- Value
- $31,538
- Van Well DaanSale
11 Sept 2026, Chief Legal Officer
- Shares
- 6,168
- Price
- $7.63
- Value
- $47,089
- Camblong JurgiSale
10 Sept 2026, Executive Chairman
- Shares
- 8,500
- Price
- $7.66
- Value
- $65,120
- Hibbs Kathy LSale
8 Sept 2026, Board
- Shares
- 6,250
- Price
- $8.13
- Value
- $50,818
- Xu ZhenyuSale
27 Aug 2026, Chief Scientific Officer
- Shares
- 10,000
- Price
- $8.91
- Value
- $89,096
- Menu PhilippeSale
25 Aug 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $8.68
- Value
- $43,397
- Hibbs Kathy LSale
25 Aug 2026, Board
- Shares
- 6,250
- Price
- $8.68
- Value
- $54,233
- Verma AbhimanyuSale
24 Aug 2026, Chief Technology Officer
- Shares
- 5,000
- Price
- $8.80
- Value
- $44,000
- Xu ZhenyuSale
21 Aug 2026, Chief Scientific Officer
- Shares
- 5,408
- Price
- $8.40
- Value
- $45,447
- Xu ZhenyuSale
20 Aug 2026, Chief Scientific Officer
- Shares
- 4,592
- Price
- $8.41
- Value
- $38,609
- Verma AbhimanyuSale
19 Aug 2026, Chief Technology Officer
- Shares
- 5,000
- Price
- $8.20
- Value
- $41,000
- Valente ManuelaSale
19 Aug 2026, Chief People Officer
- Shares
- 10,000
- Price
- $7.94
- Value
- $79,439
- Xu ZhenyuSale
19 Aug 2026, Chief Scientific Officer
- Shares
- 10,000
- Price
- $7.94
- Value
- $79,427
- Xu ZhenyuSale
13 Aug 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $7.52
- Value
- $30,076
- Menu PhilippeSale
12 Aug 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $7.52
- Value
- $37,580
- Camblong JurgiSale
10 Aug 2026, Executive Chairman
- Shares
- 8,500
- Price
- $7.61
- Value
- $64,669
- Verma AbhimanyuSale
7 Aug 2026, Chief Technology Officer
- Shares
- 5,000
- Price
- $7.60
- Value
- $38,000
- Camblong JurgiSale
7 Aug 2026, Executive Chairman
- Shares
- 20,000
- Price
- $7.23
- Value
- $144,540
- Xu ZhenyuSale
7 Aug 2026, Chief Scientific Officer
- Shares
- 17,000
- Price
- $7.29
- Value
- $123,911
- Xu ZhenyuSale
5 Aug 2026, Chief Scientific Officer
- Shares
- 3,000
- Price
- $7.00
- Value
- $21,013
- Verma AbhimanyuSale
4 Aug 2026, Chief Technology Officer
- Shares
- 5,000
- Price
- $6.95
- Value
- $34,772
- Camblong JurgiSale
4 Aug 2026, Executive Chairman
- Shares
- 20,000
- Price
- $6.92
- Value
- $138,412
- Xu ZhenyuSale
4 Aug 2026, Chief Scientific Officer
- Shares
- 10,000
- Price
- $6.92
- Value
- $69,168
- Menu PhilippeSale
27 Jul 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $5.66
- Value
- $28,306
- Camblong JurgiSale
21 Jul 2026, Executive Chairman
- Shares
- 20,000
- Price
- $6.63
- Value
- $132,654
- Camblong JurgiSale
20 Jul 2026, Executive Chairman
- Shares
- 24,381
- Price
- $6.29
- Value
- $153,445
- Menu PhilippeSale
13 Jul 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $5.70
- Value
- $28,505
- Xu ZhenyuSale
13 Jul 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $5.70
- Value
- $22,819
- Camblong JurgiSale
10 Jul 2026, Executive Chairman
- Shares
- 8,500
- Price
- $5.62
- Value
- $47,791
- Camblong JurgiSale
7 Jul 2026, Executive Chairman
- Shares
- 17,685
- Price
- $5.28
- Value
- $93,327
- Cardoza GeorgeSale
6 Jul 2026, Chief Financial Officer
- Shares
- 1,592
- Price
- $5.29
- Value
- $8,419
- Valente ManuelaSale
6 Jul 2026, Chief People Officer
- Shares
- 4,241
- Price
- $5.05
- Value
- $21,430
- Verma AbhimanyuSale
6 Jul 2026, Chief Technology Officer
- Shares
- 5,285
- Price
- $5.10
- Value
- $26,957
- Xu ZhenyuSale
6 Jul 2026, Chief Scientific Officer
- Shares
- 7,393
- Price
- $5.17
- Value
- $38,242
- Muken RossSale
6 Jul 2026, Chief Executive Officer
- Shares
- 9,838
- Price
- $5.22
- Value
- $51,354
- Puylaert KevinSale
6 Jul 2026, Chief Sales Officer
- Shares
- 216
- Price
- $5.03
- Value
- $1,087
- Menu PhilippeSale
6 Jul 2026, Chief Medical Officer
- Shares
- 7,393
- Price
- $5.16
- Value
- $38,156
- Camblong JurgiSale
6 Jul 2026, Executive Chairman
- Shares
- 22,486
- Price
- $5.26
- Value
- $118,164
- Camblong JurgiSale
30 Jun 2026, Executive Chairman
- Shares
- 65,269
- Price
- $6.11
- Value
- $398,632
- Camblong JurgiSale
29 Jun 2026, Executive Chairman
- Shares
- 18,410
- Price
- $5.87
- Value
- $108,058
- Camblong JurgiSale
26 Jun 2026, Chief Executive Officer
- Shares
- 50,069
- Price
- $5.80
- Value
- $290,329
- Camblong JurgiSale
25 Jun 2026, Chief Executive Officer
- Shares
- 1,373
- Price
- $5.70
- Value
- $7,826
- Verma AbhimanyuSale
25 Jun 2026, Chief Technology Officer
- Shares
- 6,944
- Price
- $5.51
- Value
- $38,229
- Menu PhilippeSale
25 Jun 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $5.50
- Value
- $27,525
- Cardoza GeorgeSale
22 Jun 2026, Chief Financial Officer
- Shares
- 774
- Price
- $5.38
- Value
- $4,164
- Muken RossSale
22 Jun 2026, President
- Shares
- 422
- Price
- $5.38
- Value
- $2,270
- Xu ZhenyuSale
15 Jun 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $5.01
- Value
- $20,056
- Menu PhilippeSale
12 Jun 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $4.95
- Value
- $24,752
- Camblong JurgiSale
10 Jun 2026, Chief Executive Officer
- Shares
- 8,500
- Price
- $5.24
- Value
- $44,501
- Cardoza GeorgePurchase
5 Jun 2026, Chief Financial Officer
- Shares
- 20,000
- Price
- $4.95
- Value
- $99,000
- Menu PhilippeSale
26 May 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $4.95
- Value
- $24,774
- Muken RossSale
19 May 2026, President
- Shares
- 761
- Price
- $4.60
- Value
- $3,501
- Xu ZhenyuSale
19 May 2026, Chief Scientific Officer
- Shares
- 608
- Price
- $4.60
- Value
- $2,798
- Camblong JurgiSale
19 May 2026, Chief Executive Officer
- Shares
- 4,486
- Price
- $4.60
- Value
- $20,658
- Menu PhilippeSale
19 May 2026, Chief Medical Officer
- Shares
- 608
- Price
- $4.61
- Value
- $2,800
- Van Well DaanSale
19 May 2026, Chief Legal Officer
- Shares
- 684
- Price
- $4.60
- Value
- $3,149
- Valente ManuelaSale
19 May 2026, Chief People Officer
- Shares
- 380
- Price
- $4.60
- Value
- $1,747
- Puylaert KevinSale
19 May 2026, Chief Sales Officer
- Shares
- 33
- Price
- $4.54
- Value
- $150
- Xu ZhenyuSale
13 May 2026, Chief Scientific Officer
- Shares
- 4,000
- Price
- $4.54
- Value
- $18,168
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at SOPHiA GENETICS
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- GoodRx HoldingsGDRX $1.25B58
- Omada HealthOMDA $945.45M44
- HealthStreamHSTM $883.61M62
- PhreesiaPHR $795.13M55
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- NRC HealthNRC $570.01M59
- Evolent HealthEVH $561.28M45
- CarlsmedCARL $507.83M46
ETFs that hold SOPHiA GENETICS
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 0.41% | 0.89% | €11.61M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.